Het bedrijf heeft nu meer dan 310 uitgegeven of aangevraagde patenten voor zijn innovatieve technologie om mensen met dwarslaesie te helpen
EINDHOVEN, Nederland & LAUSANNE, Zwitserland–(BUSINESS WIRE)– ONWARD Medical NV (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën ontwikkelt om beweging, onafhankelijkheid en gezondheid te herstellen bij mensen met een dwarslaesie, kondigt vandaag het bedrijf en haar partners hebben negen nieuwe patenten gekregen, waarvan zeven in samenwerking met vooraanstaande neurowetenschappelijke onderzoekslaboratoria van Caltech, UCLA, EPFL en University of Louisville.
De patenten dekken een breed scala aan technologieën en activiteiten, waaronder de implanteerbare en externe technologieplatforms van ONWARD, ARCIM en ARCEX, en beschermen de belangrijkste elementen van die systemen, zoals leadontwerpen, paradigma’s voor ruggenmergstimulatie, closed-loop controlesystemen en machine learning-algoritmen. De patenten werden toegekend in de VS, Frankrijk, Canada en Duitsland.
ONWARD Awarded Nine New Patents in Collaboration with Caltech, UCLA, EPFL, and University of Louisville
Company now has over 310 issued or pending patents covering its innovative technology to help people with spinal cord injury
EINDHOVEN, the Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)– ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the company and its partners have been awarded nine new patents, seven of them in collaboration with leading neuroscience research laboratories at Caltech, UCLA, EPFL, and University of Louisville.
The patents cover a broad range of technologies and activities encompassing ONWARD’s implantable and external technology platforms, ARCIM and ARCEX, and protecting key elements of those systems such as lead designs, spinal cord stimulation paradigms, closed-loop control systems and machine learning algorithms. The patents were awarded in the US, France, Canada, and Germany.
“Our many exclusive IP license agreements with the world’s top neuroscience research universities continue to bear fruit, adding to an already impressive IP portfolio of over 300 issued or pending patents”, said Dave Marver, Chief Executive Officer of ONWARD. “We are taking full advantage of our first-mover position to secure seminal and strategic intellectual property borne from our own engineering labs or prosecuted in collaboration with others.”
The Company has IP licensing arrangements in place with Caltech, EPFL, UCLA, University of Louisville, University of Minnesota, Univesity of British Columbia and University of Calgary.
To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
For Company Enquiries:
For Media and Investor Enquiries:
Gunther De Backer
Tel: +32 (0)475 903 909